Amgen Inc. and Gilead Sciences, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: Amgen Inc. vs. Gilead Sciences, Inc.

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Amgen Inc. and Gilead Sciences, Inc. have demonstrated distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amgen's SG&A expenses grew by approximately 31%, peaking in 2023. In contrast, Gilead Sciences saw a more dramatic increase of around 104% during the same period, reflecting a strategic shift in their operational focus.

Amgen's steady growth in SG&A spending suggests a consistent investment in marketing and administrative efficiency, while Gilead's sharper rise indicates a more aggressive expansion strategy. By 2023, both companies reached similar SG&A levels, highlighting their commitment to maintaining competitive market positions. These insights provide a window into the evolving strategies of two pharmaceutical giants, offering valuable lessons for industry stakeholders.